1. Introduction {#sec0001}
===============

White matter hyperintensities (WMH) are regions of increased signal on T2-weighted magnetic resonance imaging (MRI) sequences of the brain ([@bib0042]). The extent of WMH has been correlated with mild cognitive impairment (MCI) ([@bib0009]; [@bib0019]), dementia ([@bib0011]; [@bib0040]), as well as cortical atrophy ([@bib0005]). Besides, WMH may contribute to the progression from MCI to dementia ([@bib0040]; [@bib0039]). The severity of WMH increased among patients diagnosed as clinical or preclinical Alzheimer\'s disease (AD) ([@bib0042]; [@bib0020]), which reliably predicts who are at risk of developing AD ([@bib0028]), and predicts rate of cognitive decline among AD individuals ([@bib0029]). As for the interaction between WMH and AD pathology, WMH may not only be an independent process causing dementia in combination with coexisting yet unrelated AD pathology, but also lead directly to AD pathology by increasing amyloid accumulation rates due to ischemic disorders or by inducing ischemia because of amyloid accumulation in the vessels (cerebral amyloid angiopathy) ([@bib0008]; [@bib0007]; [@bib0033]; [@bib0027]). These lines of evidence together indicated that WMH might be involved in the pathogenesis of cognitive disorders and be promising in monitoring cognitive progression at early stage, and assessing treatment efficacy in clinical practice or drug trials.

Although previous articles have uncovered some loci that affect WMH volume (WMHV), the associations of these genetic modulators with disease risk remain poorly understood. A recent meta-analysis revealed that *PLEKHG1* was linked to WMHV and ischemic stroke, motivating further identification of WMHV-associated loci ([@bib0034]). The application of quantitative phenotypes in genome-wide association studies (GWAS) shed light on associations between genes and their correlated pathways ([@bib0030]). Moreover, MRI measurements have great strengths in monitoring changes in brain structure and function, such as adequate sensitivity, non-invasiveness, ease of access, and good tolerance ([@bib0010]). And WMHV can be reliably measured in vivo. Herein, we performed a GWAS using WMHV as an endophenotype to explore genetic predictors associated with WMHV in non-demented elders. These genetic factors may be involved in cognition-related pathophysiological processes.

2. Methods {#sec0002}
==========

2.1. Alzheimer's Disease Neuroimaging Initiative (ADNI) {#sec0003}
-------------------------------------------------------

ADNI, a large, multicenter, longitudinal neuroimaging study, was initiated in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and non-profit organizations ([@bib0023]). ADNI was established to explore the effectiveness of integrating neuroimaging, genetic/biological markers, as well as clinical and neuropsychological assessments in measuring the early diagnosis and progression of AD. Regional ethical committees of all institutions approved the ADNI study. Written informed consent was obtained from all participants or authorized representatives.

2.2. Participants {#sec0004}
-----------------

Data used in preparation for this study were derived from the ADNI database (<http://adni.loni.usc.edu/>). Baseline and longitudinal clinical and neuropsychological test results, neuroimaging scan information, and data about clinical diagnosis from all participants were available. Detailed procedures for sample screening were presented in Appendix 1. The full cohort with both GWAS and WMHV data comprised 425 subjects aged 55--80 years. To reduce the likelihood of population stratification effects in the GWAS, all samples were restricted to non-Hispanic Caucasians (*n* = 385). To avoid the influence of dementia on results, only non-demented individuals at baseline (*n =*= 355) were included in this study. To test cryptically related subjects and/or sample mix-ups, genomic identify-by-descent and multidimensional scaling (MDS) components were performed using PLINK ([@bib0006]). This step excluded 3 subjects who showed cryptically associated and clustering separately from the other participants (Appendix 2), leaving 352 valid samples. Finally, all samples presented close clustering with individuals of European descent using the HapMap cohort.

2.3. WMHV and QC {#sec0005}
----------------

WMH regions were segmented via a multimodal segmentation method, white matter lesion segmentation (WMLS), using T1-weighted and fluid-attenuated inversion recovery (FLAIR) images ([@bib0043]). FLAIR MRI was corrected for inhomogeneity and warped to T1 images to provide the segmentation. WMHs are seeded at points that are \>3.5 standard deviations (SD) from the mean signal in white matter, and final segmentation is based on a Bayesian approach, combining spatial priors and tissue class constraints. The WMH segmentation also comprised segmentations of white matter, gray matter, and cerebrospinal fluid (CSF); the sum of the tissue volumes was applied as a surrogate of intracranial volume (ICV). For analysis, WMHV values were log transformed to achieve a normal distribution because the values were skewed (Shapiro-Wilk test *P* \< 0.05). Log (WMHV) was then used as a quantitative outcome phenotype for the GWAS. QC was conducted to mitigate the influence of extreme values on statistical results. Mean and SD of baseline WMHV measures were calculated by observers blinded to clinical data, and the figures greater or smaller than 5.5-fold SD from the mean value were considered as extreme outliers and were excluded from this analysis. After removal of 2 outliers, there were 350 valid samples left.

2.4. Vascular information, neuroimaging, and cognition {#sec0006}
------------------------------------------------------

The baseline vascular information, including history of heart disease and hypertension, were accessed by screening the medical information database. Body mass index (BMI) was utilized to determine obese conditions following the world health organization criteria: overweight/obese ≥25 kg/m^2^, normal weight \<25 kg/m^2^.

Structural brain MRI was acquired using a Siemens Trio 3.0T scanner or Vision 1.5T scanner. Regional volume estimates were processed using Free-surfer software package version 4.3 and 5.1 image processing framework for the 1.5T and 3.0T MRI images, respectively. Regions of interests (ROIs) included the hippocampus and entorhinal cortex.

Cognition status was assessed by Mini-mental State Examination (MMSE) and memory (MEM) scores. The MEM was a weighted score based on memory items in Rey Auditory Verbal Learning Test (RAVLT), the Alzheimer\'s Disease Assessment Scale-Cognitive section (ADAS-cog), the MMSE and Logical Memory.

2.5. Genotyping and QC {#sec0007}
----------------------

All samples were genotyped using the Illumina Human Hap610-Quad BeadChips featuring 2379,855 single nucleotide polymorphisms (SNPs). Prior to association analysis, all samples and genotypes underwent stringent QC with the following criteria: call rates for SNPs \> 98%, call rates for individuals \> 95%, minor allele frequencies (MAF) \> 0.20 and Hardy-Weinberg equilibrium test *P* \> 0.001. We set the MAF value \> 0.20 for SNPs to improve statistical power and reduce potentially false-positive results in the context of modest sample size. Finally, the filters based on QC produced a total of 695,203 imputed and genotyped SNPs for analyses. The overall genotyping rate for the remaining dataset was 99.7%.

2.6. Statistical analyses {#sec0008}
-------------------------

Mann-Whitney U test was used to determine the difference in baseline WMHV measures of different diagnostic groups. We performed a GWAS of WMHV with genetic polymorphisms, using multiple linear regression under an additive genetic model in PLINK v1.9 software. Principle component analysis was performed in PLINK and the first three MDS components were applied as covariates in the GWAS. Age at baseline, gender, dosage of *APOE* ε4 allele, baseline diagnosis and ICV were also used as covariates. To account for multiple comparisons, we set the thresholds for genome-wide significant and suggestive associations at *P \<* 5 × 10^−8^ and *P \<* 1 × 10^−5^, respectively ([@bib0031]). Genome-wide associations were visualized using R package "qqman" and regional association plots were generated with the LocusZoom web tool (<http://locuszoom.org/>).

The difference in log (WMHV) of different genotype groups was determined using a multiple linear regression model in R software, after adjusting for age, gender and baseline diagnosis. To further explore the associations of genotypes with log (WMHV) under different vascular status, we conducted subgroup analyses by history of heart disease, history of hypertension, and obesity. As for subgroup analyses, age, gender and baseline diagnosis were also included as covariates in the multiple linear regression model. Considering the relatively low follow-up rate, we limited the maximum follow-up time to 6 years. We also calculated the relative MMSE change in percentage (yearly MMSE change/MMSE at baseline) and figures were calculated from the 1-, 2-, 3-, 4-, 5- and 6-year visits. Linear regression models were used to examine the associations of relative MMSE change in percentage with the top SNPs. Furthermore, the associations of top SNPs with MEM scores and brain structures of interest from baseline and longitudinal perspectives were also tested in R software using the multiple linear regression and linear mixed models, respectively. Age, gender, dosage of *APOE* ε4 allele, baseline diagnosis and ICV were applied as covariates.

2.7. Bioinformatics analyses {#sec0009}
----------------------------

SNP annotations were conducted via the NCBI Database of SNPs (<http://www.ncbi.nlm.nih.gov/SNP/>). Expression quantitative trait loci (eQTL) analyses were performed using multiple publicly available datasets in human brain tissues (<http://caprica.genetics.kcl.ac.uk/BRAINEAC>; Allen Institute Human Brain Atlas; <http://human.brain-map.org/>) and the whole blood (<http://www.genenetwork.nl/bloodeqtlbrowser/>).

3. Results {#sec0010}
==========

3.1. Characteristics of included subjects {#sec0011}
-----------------------------------------

Demographic characteristics of the study population are listed in [Table 1](#tbl0001){ref-type="table"} and Appendix 3. Briefly, 240 MCI (105 women, 69.6 ± 5.9 years) and 110 HC (62 women, 72.2 ± 4.1 years) subjects were enrolled from the ADNI cohort. Linear correlations between age at baseline and log (WMHV) were found in both HC (*P* = 0.0374) and MCI (*P \<* 0.0001) groups (Appendix 4). However, there was no significant difference in WMHV between males and females (MCI *P* = 0.105, HC *P* = 0.974, Total *P* = 0.153) among the diagnostic groups (Appendix 5). MCI group (45.4%) had a higher frequency of ε4 allele within *APOE* gene than HC group (29.1%) (*P* = 0.004). MCI group also had higher baseline WMHV compared to HC group (*P \<* 0.001) (Appendix 6).Table 1.Demographic information.Table 1Baseline diagnosisMCIHCTotalSample size, *n* (%)240 (68.6)110 (31.4)350Age at baseline, mean (SD)69.6 (5.9)72.2 (4.1)70.4 (5.5)Females, *n* (%)105 (43.8)62 (56.4)167 (47.7)Education years, mean (SD)16.3 (2.6)16.4 (2.5)16.3 (2.6)*APOE* ε4 carrier, *n* (%)[a](#tb1fn1){ref-type="table-fn"}109 (45.4)32 (29.1)141 (40.3)Hypertension, *n* (%)97 (40.4)47 (42.7)144 (41.1)Heart disease, *n* (%)26 (10.8)14 (12.7)40 (11.4)Obesity, *n* (%)165 (68.8)76 (69.1)241 (68.9)MMSE score at baseline, mean (SD)28.2 (1.6)29.0 (1.3)28.5 (1.5)MEM score at baseline, mean (SD)0.40 (0.66)1.09 (0.50)0.62 (0.69)WMHV at baseline, mean (SD)[b](#tb1fn2){ref-type="table-fn"}5.5 (6.6)5.3 (7.3)5.5 (6.8)[^2][^3][^4]

3.2. SNPs associated with WMHV {#sec0012}
------------------------------

A total of 350 subjects were identified for GWAS. After adjustment for age, gender, dosage of *APOE* ε4 allele, baseline diagnosis, ICV and the first three MDS components, a genome-wide significant association of rs7220676 (near *HS3ST3A1* and *MIR548H3* genes, *P* = 2.96 × 10^−8^) with WMHV was detected ([Fig. 1](#fig0001){ref-type="fig"}A). In a multiple linear regression model adjusted for age, gender and baseline diagnosis, the minor allele of rs7220676 (C) (CC: 0.2440 ± 0.5629, CT: 0.4555 ± 0.4878, TT: 0.6187 ± 0.4806; *P* = 1.34 × 10^−8^) was associated with lower log-WMHV measures in a dose-dependent manner among the whole samples ([Fig. 2](#fig0002){ref-type="fig"}). Further analysis also found this linear association of genotypes and log (WMHV) levels in both MCI (CC: 0.3071 ± 0.5543, CT: 0.4638 ± 0.4958, TT: 0.5836 ± 0.4905; *P* = 2.48 × 10^−4^) and HC (CC: 0.1060 ± 0.5569, CT: 0.4385 ± 0.4704, TT: 0.7018 ± 0.4456; *P* = 4.35 × 10^−6^) groups (Appendix 6). Regarding subgroup analyses by vascular factors, the minor allele of rs7220676 (C) was associated with lower log-WMHV measures in a dose-dependent manner both among the population without (*P* = 1.03 × 10^−5^) and with hypertension (*P* = 1.80 × 10^−4^). Furthermore, the minor allele of rs7220676 (C) was correlated with lower log-WMHV measures in a dose-dependent manner among the population without heart disease (*P* = 9.46 × 10^−10^) or with obesity (*P* = 8.33 × 10^−8^). Nonetheless, the association was not significant among those with heart disease (*P* = 0.698) or normal BMI (*P* = 0.058) (Appendix 7).Fig. 1Manhattan and regional plots for associations with white matter hyperintensity volumes. (A) Genome-wide signal intensity (Manhattan) plots showing the −log10 (*p* value) for individual single nucleotide polymorphisms. (B) Regional association results for the 12.9 Mb to 13.8 Mb region of chromosome 17. (C) Association results for the 12.9 Mb to 13.8 Mb region of chromosome 17 controlling for rs7220676.Fig. 1Fig. 2.Log (white matter hyperintensity volumes) of different genotypes. The minor allele of rs7220676 (C) showed association with log (white matter hyperintensity volumes) in a dose-dependent manner (*P* = 1.34 × 10^−8^). The *P* value was calculated using a multiple linear regression model after adjusting for age, gender and baseline diagnosis.Fig. 2

SNPs mapped closely to the top SNP (rs7220676) region were also analyzed ([Fig. 1](#fig0001){ref-type="fig"}B). These nearby SNPs showed associations with WMHV levels at *P \<* 0.01. After controlling for genotypes of rs7220676, the association signals for these nearby SNPs were dramatically attenuated ([Fig. 1](#fig0001){ref-type="fig"}C). The Quantile-Quantile plot didn\'t show evidence of spurious inflation in test statistics (the genomic inflation factor=  1) due to population stratification or other confounders (Appendix 8).

Four SNPs met criteria for suggestive levels of genome-wide significance (*P \<* 1 × 10^−5^) ([Table 2](#tbl0002){ref-type="table"}), including rs9675262 (near *HS3ST3A1* and *MIR548H3* gene, *P* = 1.15 × 10^−7^), rs9820240 (in *DCLK3* gene, *P* = 2.23 × 10^−7^), rs10916409 (near *ISCA1P2* gene, *P* = 4.55 × 10^−6^), and rs540422 (in *PICALM* gene, *P* = 9.68 × 10^−6^). The minor allele of rs9675262 (T) (*P* = 3.77 × 10^−8^), the minor allele of rs9820240 (A) (*P* = 9.73 × 10^−7^), and the minor allele of rs10916409 (C) (*P* = 1.56 × 10^−5^) were associated with lower log-WMHV measures in a dose-dependent manner among the whole samples, whereas the minor allele of rs540422 (T) (*P* = 3.01 × 10^−5^) was associated with higher log-WMHV measures in a dose-dependent manner (Appendix 9).Table 2Top SNPs associated with WMHV.Table 2CHRBPSNPMAFClosest GeneSNP Type*P*1713,392,543rs7220676C = 0.4229*HS3ST3A1, MIR548H3*intergenic2.96E-081713,395,795rs9675262T = 0.4373*HS3ST3A1, MIR548H3*intergenic1.15E-07336,796,647rs9820240A = 0.2145*DCLK3*intron2.23E-071229,156,248rs10916409C = 0.4411*ISCA1P2*intergenic4.55E-061185,707,054rs540422T = 0.3401*PICALM*intron9.68E-06[^5]

3.3. Impact of the top SNPs on cognitive scores and brain structures {#sec0013}
--------------------------------------------------------------------

Some cognitive scores (MMSE and MEM scores) and specific brain structures (hippocampal volume and entorhinal volume) were chosen as cognition-related measures. Associations of rs7220676 with the above indexes from both cross-sectional and longitudinal perspectives were determined after adjusting for age, gender, *APOE* ε4 dosage, baseline diagnosis and ICV. In total samples, rs7220676 decreased the percentage of decline in MMSE score during 1 year of follow-up (CC: −0.0164 ± 0.0639; CT: −0.0188 ± 0.0697; TT: 2.0170 × 10^−5^ ± 0.0664; *P* = 0.0479) ([Fig. 3](#fig0003){ref-type="fig"}A). MMSE scores decreased faster in subjects with TT genotypes than in those with CC genotypes (*P* = 0.0496). However, rs7220676 was not associated with MMSE% change during 2-, 3-, 4-, 5- or 6-year of follow-up. Also, rs7220676 was not correlated with MMSE scores at baseline. Besides, no significant influences of rs9675262 genotypes were revealed on MEM scores and brain structures of interest using both baseline and longitudinal measurements. In subgroup analysis, the minor allele of rs7220676 (C) was associated with slower cognitive decline assessed by MEM score in HC population (*P* = 0.0435) ([Fig. 3](#fig0003){ref-type="fig"}B), whereas no other significant associations of rs9675262 genotypes were revealed with other phenotypes of interest in HC and MCI groups.Fig. 3.Associations of rs7220676 with cognitive scores. (A) Rs7220676 was associated with the percentage of decline in Mini-mental State Examination (MMSE) score during 1 year of follow-up (*P* = 0.0479). MMSE score decreased faster in subjects with TT genotypes than those with CC genotypes (*P* = 0.0496). (B) The minor allele of rs7220676 (C) was associated with slower cognitive decline assessed by memory (MEM) score among healthy controls (*P* = 0.0435).Fig. 3

3.4. Bioinformatics analyses {#sec0014}
----------------------------

As for eQTL analyses, the minor allele of rs9820240 (A) (*P* = 0.0055) and the minor allele of rs540422 (T) (*P* = 0.04) were downregulated in putamen and frontal cortex, respectively. Besides, rs540422 has a cis-eQTL effect on *PICALM* (*Z*=  −4.57, *P* = 4.83 × 10^−6^) in whole blood (Appendix 10) ([@bib0038]).

4. Discussion {#sec0015}
=============

This study conducted a GWAS of WMHV in non-demented elders. We identified genome-wide significant associations of a novel SNP (rs7220676) near *HS3ST3A1* and *MIR548H3* genes and 4 additional suggestive association loci (in *DCLK3, PICALM* gene, near *ISCA1P2, HS3ST3A1* and *MIR548H3* genes) with baseline WMHV levels. The minor alleles of rs7220676 (C), rs9675262 (T), rs9820240 (A) and rs10916409 (C) showed association with lower log- WMHV in a dose-dependent manner, whereas the minor allele of rs540422 (T) was associated with higher log-WMHV measures in a dose-dependent manner. Besides, rs7220676 was correlated with rates of cognitive decline assessed by MMSE and MEM scores.

Both rs7220676 and rs9675262 are located on chromosome 17 near *HS3ST3A1* and *MIR548H3* genes. *HS3ST3A1* gene encodes the enzyme 3-Osulfotransferase, which catalyzes the biosynthesis of a specific subtype of heparan sulfate (HS), 3-O-sulfated heparan sulfate. *HS3ST3A1* gene has been reported to be involved in human immunodeficiency virus (HIV) infection ([@bib0016]), Plasmodium falciparum parasitaemia ([@bib0002]; [@bib0025]), lung cancer ([@bib0024]), and respiratory papillomatosis ([@bib0037]). However, no research has explored the relationships between *HS3ST3A1* gene and cognitive disorders. *MIR548H3* gene is a member of micro Ribonucleic Acid (microRNA) family, which participates in the post-transcriptional modulation of gene expression in multicellular organisms through influencing the stability and translation of messenger Ribonucleic Acids (mRNAs) ([@bib0026]). Accumulating evidence showed that microRNAs might play an important role in the development of central nervous system and neuropsychiatric diseases ([@bib0021]; [@bib0017]), and the potential associations of *MIR548H3* gene with neuroticism ([@bib0017]), epilepsy and mild intellectual disability ([@bib0004]) have been discussed in previous studies. At present, the specific mechanisms through which *MIR548H3* regulates cognition-related diseases remain poorly understood. There are several fundamental issues that need to be addressed, for example, whether microRNAs are particularly important in specific neurodegenerative diseases and which microRNA targets are linked to the disease, etc. Collectively, there is still a long way to go for research on the mechanism between the novel loci and cognitive function.

There was a suggestive SNP in the *PICALM* gene. The involvement of this gene in cognitive impairment has been highlighted. As one of the most highly validated AD risk factors, *PICALM* can be expressed in all tissues, and it shows prominent expression in neurons, where it is non-selectively distributed in the pre-and postsynaptic structures ([@bib0015]). Mutations in *PICALM* can cause synaptic perturbations, possibly through synaptic vesicle cycling, thus increasing the risk of AD. Alternatively, *PICALM* may influence AD risk through amyloid precursor protein (APP) trafficking via endocytic pathways, causing changes in amyloid beta (Aβ) levels ([@bib0015]). This evidence also got support from the biological aspect. One experiment in yeast, nematodes, and rat cortical neurons confirmed the role of *PICALM* in suppressing the toxicity of soluble Aβ oligomers and linking Aβ to the genetics of AD ([@bib0035]). Moreover, the impact of *PICALM* on disproportionate frontal damage, executive dysfunction ([@bib0022]), hippocampal degeneration ([@bib0041]), Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and frontotemporal lobar degeneration (FTLD) ([@bib0001]) provided further evidence support. However, the regions on chromosome 3 (*DCLK3*) and 1 (*ISCA1P2*) associated with WMHV have not been previously shown to have correlations with cognitive disorders. *DCLK3* can modulate the expression of many genes participating in transcriptional regulation and nucleosome/chromatin remodeling in a kinase-dependent way. The kinase that *DCLK3* expressed is preferentially distributed in neurons of the striatum and dentate gyrus, and *DCLK3* may produce neuroprotection against Huntington\'s disease ([@bib0014]). Also, *DCLK3* may promote colorectal cancer progression ([@bib0018]), and involve in the development of glaucoma ([@bib0003]). But the function of *ISCA1P2* has never been investigated. Further studies are especially warranted to explore how *DCLK3* and *ISCA1P2* genes mediate the progression of cognitive diseases.

Compared with previous articles similar to our topic ([@bib0013]; [@bib0012]; [@bib0036]; [@bib0032]), this study was conducted in a different population and has found novel loci associated with WMHV in non-demented elders. Although some suggestive SNPs didn\'t reach the genome-wide significance level, they may have the potential significance in other studies with sample enrichment. When controlling for rs7220676 genotypes, the nearby association signals diminished, which indicated that the associations in nearby loci might be driven by rs7220676. Besides, the associations of rs7220676 genotypes with WMHV were not significant among the population with heart disease or normal BMI, which may be due to the insufficient sample. Given that the relationship between rs7220676 and vascular factors has never been reported, it\'s difficult to explain the specific mechanisms. After the GWAS scan, we assessed associations of rs7220676 with other cognition-related endophenotypes. Interestingly, the minor allele of rs7220676 (C) was associated with change rate of MEM score in HC population rather than in MCI patients. It could thus reasonably be implied that the modifying effects of rs7220676 might be more evident in subjects with normal cognition. Our research suggested that rs7220676 might be associated with cognitive disease among non-demented elders, and further studies are needed to confirm this.

Some limitations must be acknowledged. Firstly, the sample size for analysis was relatively small especially in subgroup analyses, leading to limited ability to identify variants with small effects. Secondly, only non-Hispanic Caucasians were included to avoid population stratification across ethnicities, which limited the generalizability of this study. Thirdly, we applied a stringent MAF threshold (MAF \> 0.20) to improve statistical power. However, this restriction may lead to misses of less common SNPs. Fourthly, in our article, MCI patients included those who remained stable and those who developed into dementia at specific follow-up time, which may lower the specificity of the effect. However, since the conversion of MCI to dementia was complex and time-dependent, it\'s inappropriate to exclude those progressive MCI patients. The follow-up time was difficult to be defined and the follow-up data was limited. Fifthly, only the MMSE% change during 1 year of follow-up was found to be associated with rs7220676, which may be due to the higher missing rate during a longer follow-up. Replicated and independent studies with sample enrichment are warranted to confirm our findings.

In conclusion, we identified novel genome-wide significant associations of a SNP (rs7220676) near *HS3ST3A1* and *MIR548H3* genes and 4 additional suggestive association loci (in *DCLK3, PICALM* genes, near *ISCA1P2, HS3ST3A1* and *MIR548H3* genes) with baseline WMHV levels. The mechanisms underlying the associations between these novel genetic loci and cognitive disorders are worth exploring. Besides, further validation of these novel genetic associations in large samples and different populations is warranted.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: *Abbreviations: APOE, apolipoprotein E*; HC, healthy controls; MCI, mild cognitive impairment; MEM, memory; MMSE, Mini-mental State Examination; SD, standard deviation; WMHV, white matter hyperintensity volume.

[^3]: MCI group had a higher frequency of *APOE* ε4 than HC group (*P* = 0.004).

[^4]: The MCI group had higher baseline WMHV compared to HC group (*P \<* 0.001).

[^5]: *Abbreviations:* BP, base pair (variant position); CHR, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism; WMHV, white matter hyperintensity volume.
